SC-002 in Patients With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma: Phase 1 Study

High-grade pulmonary neuroendocrine tumors, including small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), represent approximately 20% of primary lung tumors and predominantly affect older patients with a smoking history [1]. Both tumor types have a poor prognosis, with limited effective available therapies. Novel therapeutic options are urgently needed to alter the natural disease course and improve survival outcomes.

Source: Lung Cancer - May 11, 2020 Category: Cancer & Oncology Authors: Daniel Morgensztern, Melissa Johnson, Charles M. Rudin, Michael Rossi, Mirella Lazarov, Daniel Brickman, Abraham Fong Source Type: research